ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Nov 18, 2021 15:28 JST
Source:
Eisai
Eisai Receives the 'Most Liked!' IR Award at The 2021 IR Award
TOKYO, Nov 18, 2021 - (JCN Newswire) - Eisai Co., Ltd. has announced that it has been selected as the winner of the "Most Liked!" IR Award at the 2021 IR Award, hosted by the Japan Investor Relations Association.
The "Most Liked!" IR Award has been newly created for commemorating the 25th anniversary of the Best IR Award in 2020. The award is designed to reflect the viewpoints of companies that applied for the IR Award based on their voting, share their proactive IR experiences, and realize best practices. The theme for 2021 is "IR activities contributing sustainability," awarding companies that have actively promoted information disclosure and their dialogue with investors on sustainability-related matters. Of the companies that applied for the 2021 IR Award, 178 companies entered the 'Most Liked!" IR Award and the top 17 companies, including Eisai, were selected based on a mutual vote by the candidate companies.
For further details, please visit the JIRA website:
https://www.jira.or.jp/english/
.
Eisai has focused on disseminating information regarding financial capital and non-financial capital value relevance that link to corporate value for longer-term as well as continuously through publicizing the results of the analysis of the correlation between ESG-related indicators and PBR (Price Book-value Ratio) , holding discussion meetings with investors, or publishing the Eisai Value Creation Report. The award was given to Eisai with "empathy" for Eisai's efforts to visualize ESG.
Eisai's corporate philosophy is to give first thought to patients and their families, and increase the benefits that health care provides as well as address diverse healthcare needs worldwide. Together with strengthening its ESG initiatives in order to realize this corporate philosophy, Eisai respects the rights of shareholders and investors, ensures fairness and transparency in management, and works on its IR activities to aid the enhancement of corporate value.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: Healthcare & Pharm
Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Motors Starts Production of Rogue Plug-in Hybrid and Navara OEM Models for Nissan
Jan 13, 2026 16:02 JST
Additional Investment in Commercial Space Station Business and Acquisition of Experimental Module Usage Rights
Jan 13, 2026 14:34 JST
Honda to Adopt New "H mark" as Symbol of Honda Automobile Business
Jan 13, 2026 11:26 JST
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
Jan 13, 2026 09:50 JST
Mazda Unveils MAZDA CX-6e New Battery EV in World Premiere
Jan 12, 2026 13:10 JST
TOYOTA GAZOO Racing Announces GR Yaris MORIZO RR
Jan 09, 2026 16:03 JST
Honda Announces New Lines of Models that Represent "Honda Sports DNA" at Tokyo Auto Salon 2026
Jan 09, 2026 14:24 JST
Honda Launches Fixed-Battery Electric Two-Wheeled Personal Commuter "Honda UC3" in Thailand and Vietnam
Jan 09, 2026 13:27 JST
Sponsorship Agreement Reached with LCR Honda; Full-Season MotoGP Entry as Pro Honda LCR
Jan 09, 2026 13:05 JST
Mazda Develops New Body Color, "Navy Blue Mica"
Jan 09, 2026 10:23 JST
Fujitsu develops digital learning platform for JAL to support self-directed learning and training management
Jan 09, 2026 10:07 JST
TOYOTA GAZOO Racing Reverting to "GAZOO Racing" to Pass on and Evolve the Making of Ever-better Cars and the Fostering of Talent
Jan 07, 2026 22:04 JST
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Release "The TANAKA 2025" a Perfume that Expresses the Fragrance of Gold (Au)
Jan 07, 2026 22:00 JST
Toyota's European R&D center changes its name and competes in WEC with a new brand
Jan 07, 2026 21:50 JST
Hitachi Launches Expanded HMAX Solutions Accelerating Social Innovation Globally Across Industries
Jan 07, 2026 12:27 JST
Mitsubishi Motors to Celebrate "Delica Festival" with Custom Versions of Delica D:5 and Delica Mini at Tokyo Auto Salon 2026
Jan 06, 2026 16:25 JST
Mitsubishi Motors Launches the Xforce in Taiwan
Jan 06, 2026 14:42 JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
Jan 06, 2026 10:43 JST
Alpha Growth plc: Alpha Longevity Management Ltd Expands Global Platform with Launch of Alpha Alternative Global Fund and Strengthening of Executive Leadership Team
Jan 05, 2026 16:00 JST
The Tampere city region chose Fujitsu to deliver and develop the area's ICT services
Jan 05, 2026 15:23 JST
More Latest Release >>
Related Release
Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
1/13/2026 9:50:00 AM JST
Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China
1/6/2026 10:43:00 AM JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
12/11/2025 7:41:00 PM JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
12/9/2025 6:51:00 PM JST
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
12/4/2025 6:36:00 PM JST
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
12/3/2025 6:19:00 PM JST
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
12/3/2025 12:01:00 AM JST
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
11/28/2025 11:00:00 PM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
11/26/2025 7:42:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
11/17/2025 10:08:00 PM JST
More Press release >>